You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Personalized Neural Stem Cell Therapy for Cancer

    SBC: Falcon Therapeutics, Inc.            Topic: NCATS

    PROJECT SUMMARY GlioblastomaGBMis an intractable cancer with an average survival time oftomonthsTreatment options are limited by the infiltration of tumor cells into healthy tissue and the difficulty of delivering effective chemotherapeutics across the blood brain barrierbut engineered neural stem cellsNSCshold great promise as GBM therapies because they selectively migrate to tumor cells and can ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Enzymatic synthesis of heparin sulfate and chondroitin sulfate

    SBC: Glycan Therapeutics LLC            Topic: 300

    Abstract This fast track STTR application proposes to synthesize structurally defined heparan sulfate and chondroitin sulfate oligosaccharides for biological researchGlycan Therapeutics is a biotech company specializing sulfated carbohydrates using innovative enzyme based methodsThis proposal is focused on the synthesis of large authentic oligosaccharides in the size range ofmers tomersas well as ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic optionsThis lack of treatment options is particularly relevant fo ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. Non-Invasive Physiologic Evaluation of Peripheral Arterial Disease

    SBC: RFPi, Inc.            Topic: NHLBI

    ABSTRACT Peripheral Arterial DiseasePADis a substantial healthcare burden in the USestimated andgtMand around the worldestimated andgtMIn the aging populationoverwith age andgtyears have PADof all patients with PAD are asymptomaticand up toof the remaining patients have atypical symptomsThe conventional ankle brachial indexcABIratio is established as the initial diagnostic evaluation in symptomati ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Ultrasound-Based Device to Guide Treatment of Graft-Versus-Host-Disease using Skin Elasticity as a Biomarker

    SBC: Microelastic Ultrasound Systems, Inc.            Topic: NCI

    Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a BiomarkerABSTRACT Sclerotic chronic graft versus host diseasecGVHDdevelops inof allogenic Human Stem Cell TransplantHCTrecipients and is associated with significant morbidity and mortalityGVHD is treated with immunosuppressionwhich puts patients at severe risk of infectionImmunosuppression must there ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Testing a male oral contraceptive targeting Eppin

    SBC: Eppin Pharma Inc            Topic: NICHD

    The global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  8. HLS- Cyclic CAR peptide: a targeted therapy for pulmonary hypertension

    SBC: VASCULAR BIOSCIENCES, INC.            Topic: NHLBI

    PUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  9. The CellRaft AIR System Workflow Automation for Stem Cell Isolation and Recovery

    SBC: Cell Microsystems, Inc.            Topic: 200

    DESCRIPTION provided by applicant Stem cell research is an emerging field with the promise of creating dramatic new approaches for disease treatment and drug discovery The research and regenerative medicine market space for stem cells is one of the most dynamic areas in the life science industry today Globally the stem cell market is growing at a CAGR of and will reach an approximate ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Nomethiazoles harnessing GABA and NO mimetic activity for Alzheimer s therapy

    SBC: sGC Pharma Inc.            Topic: NIA

    DESCRIPTION provided by applicant Alzheimerandapos s disease AD occurs in one out of eight Americans of age and affects of the elderly over Current FDA approved drugs provide short term symptomatic relief of AD There is a pressing need to discover new disease modifying medications AD is multifactorial in origin and progression A drug attenuating several underlying factors is a p ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government